Session » Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Date: Monday, November 6, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1163

A First-in-Human Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Novel Anti-Interleukin 1 Biologic Agent, Rph-104, in Healthy Subjects

9:00AM-11:00AM: Abstract Number: 1179

A Multi-Organ Inflammatory Condition with Features of Idiopathic Multicentric Castleman’s Disease and IgG4-Related Disease: An Unrecognized Mimicker of IgG4-RD

9:00AM-11:00AM: Abstract Number: 1176

A Randomized, Open-Label, Dose-Ranging Study of Oral Delayed Release Prednisone in Patients with Untreated Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 1177

Airway Findings in Patients with Relapsing Polychondritis

9:00AM-11:00AM: Abstract Number: 1148

Arthritis after Cancer Immunotherapy: Symptom Duration and Treatment Response

9:00AM-11:00AM: Abstract Number: 1182

Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events

9:00AM-11:00AM: Abstract Number: 1183

Bone Sarcoidosis: A Multicenter Study

9:00AM-11:00AM: Abstract Number: 1161

Clinical Characteristics of Ocular Sarcoidosis: A Population Based Study 1976-2013

9:00AM-11:00AM: Abstract Number: 1165

Clinical Characteristics of Patients with Late-Onset Familial Mediterranean Fever in Japan

9:00AM-11:00AM: Abstract Number: 1149

Clinical Implications of Ultrasonography (US) in Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparative Investigation By US between Auricle of RP, Repeated Trauma and Healthy Subject

9:00AM-11:00AM: Abstract Number: 1151

Clinical Manifestations of BehçEt’s Disease Depending on Sex and Age: Nationwide Japanese Registration

9:00AM-11:00AM: Abstract Number: 1168

Eosinophilic Fasciitis: Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients

9:00AM-11:00AM: Abstract Number: 1170

High Output Flow Cytometry Array Classifies Subjects with Uveitis Due to Behcet’s Disease and Sarcoidosis

9:00AM-11:00AM: Abstract Number: 1157

Hypocomplementemia Is Closely Related to IgG Subclasses Other Than IgG4 in IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1155

Impact of Adalimumab on Immunosuppressant Use in Patients with Active and Inactive Non-Infectious Intermediate, Posterior, or Pan-Uveitis in the Ongoing Open Label Study: Visual-III

9:00AM-11:00AM: Abstract Number: 1162

Impact of Bone Localization on the Prognostic of Langerhans Cell Histiocytosis: A Monocentric Retrospective Study

9:00AM-11:00AM: Abstract Number: 1160

Increased Incidence of Upper and Lower Gastrointestinal Events in Patients with Sarcoidosis: A Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 1152

Interleukin-37 As an Independent Disease Activity Marker of Adult-Onset Still’s Disease

9:00AM-11:00AM: Abstract Number: 1147

Macrophage Activation Syndrome or Acquired Hemophagocytic Lymphohistiocytosis in Adults: Demographics, Clinical Characteristics, and Survivorship in an American Academic Medical Center

9:00AM-11:00AM: Abstract Number: 1180

Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis

9:00AM-11:00AM: Abstract Number: 1171

Mycophenolate Mofetil May Improve Interstitial Pneumonia with Autoimmune Features

9:00AM-11:00AM: Abstract Number: 1159

National Recommendations on the Use of Immunomodulatory Drugs in Patients with NON-Infectious NON-Malignant Anterior Uveitis

9:00AM-11:00AM: Abstract Number: 1150

Ocular Involvement Is Exclusive with Genital Ulcer and Skin Lesion in the Early Phase of Behçet’s Disease: Nationwide Japanese Registration.

9:00AM-11:00AM: Abstract Number: 1167

Phenotypical Features of Patients with Rheumatologic Manifestations of Common Variable Immunodeficiency

9:00AM-11:00AM: Abstract Number: 1169

Rapid Improvement with Tocilizumab in Refractory and Severe Uveitic Cystoid Macular Edema

9:00AM-11:00AM: Abstract Number: 1184

Response to Methotrexate and Glucocorticoid Injection in New Onset Arthritis after Checkpoint Inhibitor Therapy

9:00AM-11:00AM: Abstract Number: 1173

Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort

9:00AM-11:00AM: Abstract Number: 1156

Rheumatic Immune Related Adverse Events from Checkpoint Inhibitor Therapy for Cancer: Long-Term Follow up Data

9:00AM-11:00AM: Abstract Number: 1153

Rheumatic Manifestations of Whim Syndrome

9:00AM-11:00AM: Abstract Number: 1175

Rituximab for Idiopathic and IgG4-Related Retroperitoneal Fibrosis

9:00AM-11:00AM: Abstract Number: 1181

Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease

9:00AM-11:00AM: Abstract Number: 1164

Spectrum of Skin Eruption and Histological Findings in Adult-Onset Still’s Disease and Significance of Atypical Persistent Skin Eruptions

9:00AM-11:00AM: Abstract Number: 1178

Sympathetic Joint Effusion in an Urban Hospital

9:00AM-11:00AM: Abstract Number: 1166

Systemic Degos Disease: Long Term Survival on Combined Therapy with Eculizumab and Treprostinil

9:00AM-11:00AM: Abstract Number: 1158

Treatment of Non-Infectious Uveitis: A Comparative Long-Term Study between Biologic Therapy with Adalimumab and Two Conventional Disease-Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 1154

Use of Including Serum Ferritin and Heme Oxygenase 1 in the Yamaguchi’s Classification for Adult-Onset Still’s Disease: A Multicenter Retrospective Study

9:00AM-11:00AM: Abstract Number: 1172

Utility of Interstitial Pneumonia with Autoimmune Features (IPAF) Proposed Criteria in the Classification of Patients with CTD-Associated Interstitial Lung Disease in a Single Centre

9:00AM-11:00AM: Abstract Number: 1174

Which Definition Should be Used to Determine Colchicine Resistance in Patients with Familial Mediterranean Fever?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].